metacrine logo metacrine about leadership ken song md president and ceo ken song serves as president and ceo and board member of metacrine dr song’s experience spans clinical medicine basic science research venture capital and entrepreneurship prior to joining metacrine he was the cofounder and ceo of ariosa diagnostics from  to  at ariosa he was coinventor of the flagship product and successfully led the organization from early research to product development to commercialization in over  countries ariosa was acquired by roche in early  for m from  to  dr song was a venture capital investor at venrock where he led investments in both private and public therapeutic medical device and diagnostic companies dr song trained in internal medicine at the university of california san francisco ucsf and then went on to specialize in gastroenterology and hepatology at the university of washington along with a scientific fellowship at the fred hutchinson cancer center he also spent several years as a consultant at mckinsey  company focusing on early stage life science companies dr song received his bs in biology from the massachusetts institute of technology and his md from ucsf trisha millican cfo trisha millican serves as the chief financial officer of metacrine inc mrs millican’s experience includes corporate finance corporate and business development and business operations prior to joining metacrine she was senior vice president of finance of seragon pharmaceuticals she led corporate finance and was a key player in the sale to genentechroche in august  for up to  billion prior to joining seragon she served as vice president of finance at aragon pharmaceuticals inc until its sale in august  to johnson  johnson for up to  billion she has over  years of finance experience in healthcare serving in various senior financial management roles including zogenix inc a publiclytraded specialty biotechnology company from september  to august  and metabasis therapeutics inc a publiclytraded biotechnology company until its sale in  mrs millican spent five years with the public accounting firm deloitte is a certified public accountant in the state of california and holds a bs in accounting from the university of san diego nicholas smith phd senior vice president chemistry dr smith is the senior vice president of chemistry for metacrine inc he has more than 8 years drug discovery experience in the pharmaceutical industry both in biotech and big pharma most recently at seragon pharmaceuticals acquired by roche in  for m upfront and up to b in milestones and aragon pharmaceuticals acquired by johnson  johnson in  for m up front and m in milestones dr smith was vice president of chemistry where he oversaw medicinal chemistry projects including the delivery of two estrogen receptor degrader serd clinical candidates and a nextgeneration androgen receptor antagonist program in addition dr smith was responsible for the aragon and then seragon ip portfolios and aspects of cmc prior to aragon pharmaceuticals dr smith was head of chemistry at kalypsys pharmaceuticals where he oversaw a number of medicinal chemistry projects and led teams that delivered clinical candidates in the therapeutic areas of oncology and pain prior to kalypsys dr smith was a research fellow at merck  co where he led chemistry groups that contributed to clinical candidates in the areas of obesity and inflammation dr smith was a postdoctoral fellow at the university of toronto and has a phd in synthetic organic chemistry from the university of southampton uk eric bischoff vice president development and operations eric bischoff is the vice president of business operations for metacrine inc mr bischoff has a strong multidisciplinary background in metabolic disease and oncology targets with over  years of experience in the biotechpharmaceutical industry prior to joining metacrine he served as senior director of business operations and contracts at seragon pharmaceuticals a private oncology drug discovery and development company where he oversaw company operations and contracts at seragon he was involved in business development efforts resulting in the b acquisition of seragon pharmaceuticals by genentech a member of the roche group for an upfront payment of m and b in contingent development milestones prior to seragon mr bischoff served as director of operations at aragon pharmaceuticals which was acquired by johnson  johnson for b prior to aragon he worked as a pharmacologist at companies including xceptor therapeutics acquired by exelixis ligand pharmaceuticals and hybritech inc mr bischoff received his bs in biology from the university of california at san diego brandee wagner phd director biology brandee wagner serves as the director of biology dr wagner has more than  years drug discovery experience in the pharmaceutical industry focused exclusively on metabolic disease targets most recently she was a research fellow at regulus therapeutics from  to  leading a project developing an antimir targeting microrna for the treatment of nonalcoholic steatohepatitis nash in patients with type  diabetes under a strategic alliance with astrazeneca in late  regulus and astrazeneca announced the initiation of phase  for the clinical candidate rg azd from  to  she was a research scientist at arena pharmaceuticals exelixis and xceptor therapeutics focusing on gpcrs and nuclear receptors in metabolic disease dr wagner obtained her phd at duke university and was a postdoctoral fellow at the salk institute and the joslin diabetes center mack flinspach phd director protein engineering mack flinspach serves as the director of protein engineering at metacrine dr flinspach’s experience spans biotherapeutic drug discovery protein engineering and structural biology prior to joining metacrine he was the lead peptide engineer for the aranea internal venture at janssen pharmaceutical companies of johnson  johnson from  to  at aranea he coled an interdisciplinary project team targeting nav to nme using an engineered spider venom peptide approach from  to  dr flinspach was a project team leader and protein expression group leader in biologics research west coast within janssen rd working on lead discovery and optimization of monoclonal antibodies alternative scaffolds and peptides across a wide variety of therapeutic areas from  to  dr flinspach was a staff scientist in structural biology at senomyx inc dr flinspach trained in structural biology at the university of california irvine and did his postdoctoral training at the salk institute and the genomics institute of the novartis research foundation dr flinspach earned his ba in biology from california state university san bernardino and his phd in biological sciences from the university of california irvine home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine efficiently developing innovativedrugs that materially benefitpatients with metabolic disease about metacrine metacrine is a privately held biotech company founded in  on technology licensed from the laboratory of dr ronald evans a world leader in nuclear hormone receptors and howard hughes medical institute investigator at the salk institute metacrine will leverage two mechanistically distinct programs to target diabetes steatohepatitis and other metabolic and liver disorders learn more about metacrine latest news  metacrine to present two abstracts on its novel fxr nonbile acid agonist program at the easl international liver congress   metacrine expands patent portfolio for novel fgf program to treat diabetes see all news contact us metacrine inc 8 el camino real suite  san diego ca  p  8 f  8 information infometacrinecom employmentcareersmetacrinecom home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine about leadership ken song md president and ceo ken song serves as president and ceo and board member of metacrine dr song’s experience spans clinical medicine basic science research venture capital and entrepreneurship prior to joining metacrine he was the cofounder and ceo of ariosa diagnostics from  to  at ariosa he was coinventor of the flagship product and successfully led the organization from early research to product development to commercialization in over  countries ariosa was acquired by roche in early  for m from  to  dr song was a venture capital investor at venrock where he led investments in both private and public therapeutic medical device and diagnostic companies dr song trained in internal medicine at the university of california san francisco ucsf and then went on to specialize in gastroenterology and hepatology at the university of washington along with a scientific fellowship at the fred hutchinson cancer center he also spent several years as a consultant at mckinsey  company focusing on early stage life science companies dr song received his bs in biology from the massachusetts institute of technology and his md from ucsf trisha millican cfo trisha millican serves as the chief financial officer of metacrine inc mrs millican’s experience includes corporate finance corporate and business development and business operations prior to joining metacrine she was senior vice president of finance of seragon pharmaceuticals she led corporate finance and was a key player in the sale to genentechroche in august  for up to  billion prior to joining seragon she served as vice president of finance at aragon pharmaceuticals inc until its sale in august  to johnson  johnson for up to  billion she has over  years of finance experience in healthcare serving in various senior financial management roles including zogenix inc a publiclytraded specialty biotechnology company from september  to august  and metabasis therapeutics inc a publiclytraded biotechnology company until its sale in  mrs millican spent five years with the public accounting firm deloitte is a certified public accountant in the state of california and holds a bs in accounting from the university of san diego nicholas smith phd senior vice president chemistry dr smith is the senior vice president of chemistry for metacrine inc he has more than 8 years drug discovery experience in the pharmaceutical industry both in biotech and big pharma most recently at seragon pharmaceuticals acquired by roche in  for m upfront and up to b in milestones and aragon pharmaceuticals acquired by johnson  johnson in  for m up front and m in milestones dr smith was vice president of chemistry where he oversaw medicinal chemistry projects including the delivery of two estrogen receptor degrader serd clinical candidates and a nextgeneration androgen receptor antagonist program in addition dr smith was responsible for the aragon and then seragon ip portfolios and aspects of cmc prior to aragon pharmaceuticals dr smith was head of chemistry at kalypsys pharmaceuticals where he oversaw a number of medicinal chemistry projects and led teams that delivered clinical candidates in the therapeutic areas of oncology and pain prior to kalypsys dr smith was a research fellow at merck  co where he led chemistry groups that contributed to clinical candidates in the areas of obesity and inflammation dr smith was a postdoctoral fellow at the university of toronto and has a phd in synthetic organic chemistry from the university of southampton uk eric bischoff vice president development and operations eric bischoff is the vice president of business operations for metacrine inc mr bischoff has a strong multidisciplinary background in metabolic disease and oncology targets with over  years of experience in the biotechpharmaceutical industry prior to joining metacrine he served as senior director of business operations and contracts at seragon pharmaceuticals a private oncology drug discovery and development company where he oversaw company operations and contracts at seragon he was involved in business development efforts resulting in the b acquisition of seragon pharmaceuticals by genentech a member of the roche group for an upfront payment of m and b in contingent development milestones prior to seragon mr bischoff served as director of operations at aragon pharmaceuticals which was acquired by johnson  johnson for b prior to aragon he worked as a pharmacologist at companies including xceptor therapeutics acquired by exelixis ligand pharmaceuticals and hybritech inc mr bischoff received his bs in biology from the university of california at san diego brandee wagner phd director biology brandee wagner serves as the director of biology dr wagner has more than  years drug discovery experience in the pharmaceutical industry focused exclusively on metabolic disease targets most recently she was a research fellow at regulus therapeutics from  to  leading a project developing an antimir targeting microrna for the treatment of nonalcoholic steatohepatitis nash in patients with type  diabetes under a strategic alliance with astrazeneca in late  regulus and astrazeneca announced the initiation of phase  for the clinical candidate rg azd from  to  she was a research scientist at arena pharmaceuticals exelixis and xceptor therapeutics focusing on gpcrs and nuclear receptors in metabolic disease dr wagner obtained her phd at duke university and was a postdoctoral fellow at the salk institute and the joslin diabetes center mack flinspach phd director protein engineering mack flinspach serves as the director of protein engineering at metacrine dr flinspach’s experience spans biotherapeutic drug discovery protein engineering and structural biology prior to joining metacrine he was the lead peptide engineer for the aranea internal venture at janssen pharmaceutical companies of johnson  johnson from  to  at aranea he coled an interdisciplinary project team targeting nav to nme using an engineered spider venom peptide approach from  to  dr flinspach was a project team leader and protein expression group leader in biologics research west coast within janssen rd working on lead discovery and optimization of monoclonal antibodies alternative scaffolds and peptides across a wide variety of therapeutic areas from  to  dr flinspach was a staff scientist in structural biology at senomyx inc dr flinspach trained in structural biology at the university of california irvine and did his postdoctoral training at the salk institute and the genomics institute of the novartis research foundation dr flinspach earned his ba in biology from california state university san bernardino and his phd in biological sciences from the university of california irvine home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine about targeting metabolic disease through advances in endocrine research metacrine is a biotech company developing innovative therapeutics for metabolic diseases the company is led by an experienced management team and backed by leading institutional investors founded in  metacrine’s initial technology was licensed from the laboratory of dr ronald evans a world leader in nuclear hormone receptors and howard hughes medical institute investigator at the salk institute the current focus of the company is to develop novel therapeutics for significant metabolic diseases such as type  diabetes and nonalcoholic steatohepatitis nash there are over  million type  diabetics in the united states and despite numerous available drug classes close to  of patients are unable to achieve target hbac levels and glucose control similarly nonalcoholic steatohepatitis nash is reaching epidemic proportions in the us and worldwide with nearly  of americans having some stage of fatty liver disease currently there is no approved therapy for nash metacrine will leverage two mechanistically distinct programs to target type  diabetes nash and other metabolic diseases and liver disorders home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine contact location metacrine inc 8 el camino real suite  san diego ca  p  8 f  8 email contacts information infometacrinecom employment careersmetacrinecom home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine about board of directors rich heyman phd executive chairman of the board founder richard heyman phd served as ceo of seragon pharmaceuticals until march  seragon was a san diego based biotech company that that focused on the development of selective estrogen receptor degraders serds targeting estrogen dependent cancers in august  genentechroche acquired seragon prior to seragon he cofounded and was ceo of aragon pharmaceuticals which developed next generation therapeutics for hormone dependent cancers based on new insights into molecular mechanisms of resistance johnson  johnson purchased aragon in august  and simultaneous with this acquisition seragon pharmaceuticals was spun out and created previously he cofounded and served as chief scientific officer of xceptor therapeutics a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases which was acquired by exelixis in  prior to xceptor he held various roles at ligand pharmaceuticals including vice president of research where he served as project leader leading to the successful identification and development of panretin® and targretin® retinoids approved by the fda for the treatment of cancer he is the author or inventor on more than  publications and patents he serves on the board of trustees of the salk institute for biological studies and is a board member of receptos inc organovo inc and biocom he is also a member of the therapeutic advisory board for atyr pharma and serves on the executive committee of the ucsd moores cancer center he was an nih postdoctoral fellow and staff scientist at the salk institute working with dr ronald evans he received a phd in pharmacology from the university of minnesota and a bs in chemistry from the university of connecticut robert adelman md director robert adelman has a year history of founding investing in and managing companies in the life sciences sector he received his undergraduate degree from the university of california at berkeley his medical degree from yale university performed his residency at cornell university medical center and practiced surgery in new york and new jersey before founding venbio he had a sevenyear tenure as a private equity partner at orbimed advisors there he was part of a team that invested b in both private and public companies across three venture capital funds he has cofounded a number of biotech companies he led venbio’s investment into aragon pharmaceuticals where he joined the board of directors and remained on the board until the company’s acquisition by johnson  johnson he also led the investment into seragon pharmaceuticals where he joined the board of directors and remained on the board until the company’s acquisition by genentechroche he coled venbio’s investment into solstice biologics and heart metabolics and currently serves on the board at both companies kristina burrow director kristina burow is a managing director with arch venture partners specializing in biotechnology pharmaceuticals chemicals and alternative energy companies   she is a cofounder of sapphire energy and a director of receptos rcpt lycera trelys cenexys agbiome scholar rock and kilimanjaro energy she has participated in the funding and development of siluria technologies ensemble therapeutics kythera biopharmaceuticals kyth ikaria achaogen quanterix and accelerator corporation  prior to arch she was an associate with the novartis bioventure fund in san diego where she was involved in numerous investments in the life science sector as an early employee at the genomics institute of the novartis research foundation gnf she directed chemistry operations and was active in business development where she helped create numerous companies as spin outs from gnf  she holds a mba from the university of chicago a ma in chemistry from columbia university and a bs in chemistry from the university of california berkeley amir nashat phd director amir nashat is a managing partner in polaris’ boston office he joined polaris in april  and focuses on investments in healthcare consumer products and energy he currently represents polaris as a director of agbiome atyr pharmaceuticals bind therapeutics nasdaq bind fate therapeutics nasdaq fate promedior pharmaceuticals scholar rock and selecta biosciences additionally he has served as a director of adnexus therapeutics acquired by bristol myers squibb athenix corporation acquired by bayer avila therapeutics acquired by celgene living proof pervasis therapeutics acquired by shire pharmaceuticals receptos nasdaq rcpt sun catalytix acquired by lockheed martin and served as a board observer of gi dynamics gidax in addition to his role as an investor he has also served as the initial ceo of living proof known as andora at the time and sun catalytix corporation prior to joining polaris he completed his phd as a hertz fellow in chemical engineering at the massachusetts institute of technology with a minor in biology under the guidance of dr robert langer he also earned both his ms and bs in materials science and mechanical engineering at the university of california berkeley he serves on the partners innovation fund and is a catalyst of the deshpande center for technological innovation at mit he previously served on the board of the new england venture capital association he has been named to the forbes midas list of top  venture capitalists ronald evans phd independent director founder ronald evans is an investigator of the howard hughes medical institute and director of the gene expression laboratory at the salk institute he is known for his discoveries of nuclear receptors and the mechanism of hormone signaling hormone receptors help to control sugar salt calcium and fat metabolism as well as reproductive physiology these receptors are primary targets in the treatment of breast cancer prostate cancer and leukemia as well as osteoporosis inflammation and asthma his initial isolation of steroid receptors uncovered a hidden ‘superfamily’ of hormone receptors whose characterization revealed the existence of previously unknown signaling pathways for cholesterol bile acids and fatty acids fundamentally changing our views of both physiology and the treatment of disease such as obesity diabetes and cancer his work led to the development of panretin targretin in leukemia ligand pharmaceuticals as well as lasofoxifene and bazedoxifene pfizer for osteoporosis and hormone replacement therapy he was a cofounder of xceptor therapeutics a company that developed compounds targeting orphan nuclear receptors for the treatment of metabolic diseases which was acquired by exelixis in  he was a consultant for the development of aragon arn and seragon arn8 for prostate and breast cancer respectively he is a founder of mitobridge in boston developing drugs to boost mitochondrial function and xtuit building drugs to target the tumor microenvironment his current work focuses on energy metabolism in muscle exercise in a pill along with new insights into obesity insulin resistance and cancer he is a professor in the gene expression laboratory at the salk institute for biological studies a howard hughes medical institute investigator and holds the march of dimes chair in developmental and molecular biology at the salk institute and a research scholar of the lustgarten foundation for pancreatic cancer he is the recipient of the albert lasker award  the wolf prize israel  and a member of the national academy of sciences and the institute of medicine ken song md president and ceo director home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine news metacrine to present two abstracts on its novel fxr nonbile acid agonist program at the easl international liver congress  april   san diego ca  metacrine inc a leading and innovative biotechnology company focused on drug development for metabolic diseases announced it will present two abstracts on its novel fxr agonist program at the upcoming international liver congress meeting of the european association for the study of liver disease easl in amsterdam netherlands metacrine has developed a leading and comprehensive fxr agonist program based on a unique nonbile acid chemical scaffold  read more metacrine expands patent portfolio for novel fgf program to treat diabetes october   san diego ca  metacrine inc a leading biotechnology company efficiently developing innovative drugs for metabolic diseases announced the issuance of a new patent by the us patent and trademark office that supports development for the company’s fgf program  read more metacrine announces appointment of dr ken song as president and chief executive officer september   san diego ca  metacrine inc a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research today announced the appointment of ken song md as its new president chief executive officer and director  read more metacrine raises  million in series a financing august   san diego ca  metacrine inc a biotechnology company focused on targeting metabolic disease through advances in endocrine research today announced it has raised  million in a series a financing read more home about overview leadership board of directors scientific founders investors news contact x metacrine logo metacrine investors wwwarchventurecom wwwvenbiocom wwwarecom wwwpolarispartnerscom home about overview leadership board of directors scientific founders investors news contact x metacrine inc company profile  bloomberg feedback metacrine inc private company company profile sector health care industry biotech  pharma subindustry biotech corporate information address  glen avenue suite  san diego ca  united states phone  fax  board members chairmancofounder company richard heyman metacrine inc presidentceo company kenneth song metacrine inc board members company robert adelman venbio partners llc amir nashat polaris venture partners lp kristina burow arch venture partners lp from the web key executives richard a heyman chairmancofounder kenneth song ken presidentceo trisha m millican chief financial officer sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data metacrine inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       metacrine inc print preview export bookmark share with colleague general information  location san diego calif  region san diego  country us  business category endocrinemetabolic hepatic  year founded   website  lead product status nd  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy ken song  metacrine inc  email ceo metacrinecom cfo login  day free trial metacrine inc metacrinecom 8 el camino real san diego ca  phone 8 fax 8 type private employees not available revenue    million industry biotechhealthcare sic code 8  biological products except diagnostic view employees it intelligence news currently hiring historical trends it intelligence no categories no products found helpful hint the inside view displays a list of technologies and products used internally at a company f i r e w a l l show all analytics google analytics google analytics shows you the full customer picture across ads and videos websites and social tools tablets and smartphones that makes it easier to serve your current customers and win new ones sign up to see all helpful hint the outside view displays all the technologies and devices which can be seen on the internet news and background news and background company in the news september    new hire nametitleken songpresidentceo read entire article sign up to see all press events background full company description is available with the free trial name email address department get data ken song title president and ceo no email avail executive export trisha millican title cfo no email avail finance export ken song title presidentceo no email avail executive export eric bischoff title vice president business operations free trial for email operations export nicholas smith title senior vice president chemistry no email avail medical  science export brandee wagner title director biology no email avail medical  science export showing  to  of  entries level and organization level and organization historical trends historical trends yearly quarterly weekly quarterly poll question date created current result votes only for logged in user additional info metacrine inc is a company that works within the biotechhealthcare this san diego cabased business their profile on lead presents significant contact information such as cfo contacts phone numbers linkedin data and metacrine inc email format addresses with the metacrinecom domain as well as quality contact info regarding metacrine incs ceo ken song they have their head office in san diego ca if you sign up for our free trial you will see our emailmetacrinecom addresses company background full company description is available with the free trial ceo reference ken song their president and ceo is ken song their lead profile is categorized under the biotechhealthcare industry if youre checking for metacrine inc email addresses these are also available on lead with the metacrinecom email addresses and possibly ken songs email metacrine inc is based in san diego ca you can also get ken songs linkedin info twitter data phone numbers wiki and biography on their lead profile their contact information is filed under the biotechhealthcare category some possible email formats for ken song are ksongmetacrinecom kensongmetacrinecom kenmetacrinecom and kensongmetacrinecom if you sign up for our free trial you will see our emailmetacrinecom addresses similar companies activx biosciences lead offers quality contact information on a variety of companies including that of activx biosciencess ceo  the company profile also contains facebook info linkedin accounts phone numbers cfo contacts and activx biosciences email addresses with the domain format of activxcom activx biosciences is in the biotechhealthcare field if you sign up for our free trial you will see our emailactivxcom addresses xencor xencor a biotechhealthcare company is based in monrovia ca they can be reached through xencor email format addresses indicated on their lead profile with a domain of xencorcom if you sign up for our free trial you will see our emailxencorcom addresses molecularware molecularware a business led by ceo richard kivel is part of the biotechhealthcare industry molecularware email with the molecularwarecom format you can check their lead profile they hold their main office in irvine ca and more data like cfo contacts and linkedin data can be found within our profiles if you sign up for our free trial you will see our emailmolecularwarecom addresses company directory  metacrine inc metacrine company profile  owler we just sent you an email to verify your account check your inbox     resend verification link  sign in sign in sign up you have just joined  metacrine announces appointment of dr ken song as president and chief executive officer metacrine announces appointment of dr ken song as president and chief executive officer news provided by metacrine sep   8 et share this article san diego sept   prnewswire  metacrine inc a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research today announced the appointment of ken song md as its new president chief executive officer and director  dr song was most recently cofounder and chief executive officer of ariosa diagnostics which was acquired by roche in  for  million kens proven leadership track record and broad expertise serving the life science community over the last several years will build on metacrines progress as it continues to advance its therapeutic pipeline and drive to important milestones said richard heyman chairman of the board of directors of metacrine we are very excited about the prospects of the companys evolution under kens leadership as the company progresses toward the clinical advancement of its programs dr songs experience spans clinical medicine basic science research venture capital and entrepreneurship  as coinventor of ariosas flagship product he successfully led the organization from early research to product development to commercialization in over  countries prior to ariosa dr song was a venture capital investor at venrock and served as a consultant at mckinsey  company dr song trained in internal medicine at the university of california san francisco ucsf and then went on to specialize in gastroenterology and hepatology at the university of washington along with a scientific fellowship at the fred hutchinson cancer center he received his bs in biology from the massachusetts institute of technology and his md from the university of california san francisco im thrilled to have the opportunity to lead metacrine and work with an outstanding team and group of investors said dr song with the companys two mechanistically distinct programs targeting large clinical needs i believe metacrine has the potential to bring forth novel medicines that can positively impact tens of millions of people about metacrine metacrine is a privatelyheld biotechnology company headquartered in san diego ca the company is focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases for more information visit wwwmetacrinecom contact  julie rathbun rathbun communicationsjulierathbuncommcom                                              logo  httpphotosprnewswirecomprnhlogo   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesmetacrineannouncesappointmentofdrkensongaspresidentandchiefexecutiveofficerhtml source metacrine related links httpwwwmetacrinecom oct    et preview metacrine expands patent portfolio for novel fgf program to treat diabetes aug    et preview metacrine raises  million in series a financing my news release contains wide tables view fullscreen also from this source apr   8 et metacrine to present two abstracts on its novel fxr nonbile acid explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals personnel announcements you just read metacrine announces appointment of dr ken song as president and chief executive officer news provided by metacrine sep   8 et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search   scrip in order to deliver a personalized responsive service and to improve the site we remember and store information about how you use it this is done using simple text files called cookies which sit on your computer by continuing to use this site and access its features you are consenting to our use of cookies to find out more about the way informa uses cookies please go to our cookie policy page scrip is part of the business intelligence division of informa plc informa plc about us investor relations talent this site is operated by a business or businesses owned by informa plc and all copyright resides with them informa plc’s registered office is  howick place london swp wg registered in england and wales number 88 informa toggle menu menu other publications in vivo  medtech insight  pink sheet  rose sheet  register sign in this copy is for your personal noncommercial use for highquality copies or electronic reprints for distribution to colleagues or customers please call     8 printed by usernamepublicrestriction already registered sign in to continue reading your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at      us support at     or onlineaccessinformacom new to scrip request a free trial today free trial register for our free email digests your username does not meet the requirements an account with that username already exists unfortunately weve not been able to process your registration please contact support register toggle menu menu home commercial companies deals strategy market access market intelligence appointments research  development clinical trials approvals therapy areas pipeline watch policy  regulation hot topics us election  pricing debate brexit regional coverage meet the team scrip awards scrip  scrip asia  ask the analyst pdf library rss feeds free trial request subscribe advertise usernamepublicrestriction already registered sign in to continue reading your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at      us support at     or onlineaccessinformacom new to scrip request a free trial today free trial register for our free email digests your username does not meet the requirements an account with that username already exists unfortunately weve not been able to process your registration please contact support register email share metacrine inc wwwmetacrinecom latest from btg plc bookmark 8 jul  analysis immunooncology outlook bavencio leads pdl pack in ovarian cancer by lucie ellis merck kgaapfizers bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but roches tecentriq is hot on its heels the ovarian cancer pipeline boasts seven other latestage drugs including antibodydrug conjugates and small molecules that are ready to ramp up competition on the market clinical trials immunooncology bookmark  may  analysis btgs louise makin on joining io agents and localized intervention by sten stovall btgs ceo says combining novel immunooncology therapies with imageguided minimally invasive therapies could deliver treatments where needed while lowering overall treatment costs business strategies companies bookmark  may  analysis when two worlds collide – btg brings interventional oncology and immunotherapy together by ashley yeo btgs range of interventional oncology technologies puts it in an enviable position in rd initiatives that require a holistic view across cancer and the besttargeted therapies the uklisted company will now take this to another level following an agreement with the society of interventional oncology to explore the role of minimally invasive therapies in immunooncology immunooncology research and development strategies bookmark  mar  news btg set to launch first radiopaque drugeluting bead in the eu by reed miller dc bead lumi is designed to be loaded with doxorubicin or irinotecan to treat liver cancer while showing the treating physician where it is to improve control of transarterial chemoembolization procedures cancer innovation see all company information industry biotechnology pharmaceuticals therapeutic areas hepatic liver metabolic disorders aliases ownership private headquarters worldwide north america usa company type startup parent  subsidiaries metacrine inc senior management ken song pres  ceotrisha millican cfo contact info metacrine inc phone  8 8 el camino real ste  san diego ca  usa advertisement advertisement you must sign in to use this functionality your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at      us support at     or onlineaccessinformacom authenticationsigninheadsigninheader your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at      us support at     or onlineaccessinformacom usernamepublicrestriction register your username does not meet the requirements sorry  this email domain is not allowed sorry  public email accounts are not allowed please provide a work email address an account with that username already exists unfortunately weve not been able to process your registration please contact support register metacrine inc email company all set this article has been sent to myemailaddress all fields are required for multiple recipients separate email addresses with a semicolon please make sure all fields are completed please enter a valid email address please make sure you have filled out all fields please make sure you have filled out all fields subject metacrine inc add a personalized message to your email cancel send dcdemailpopoutnotice × this copy is for your personal noncommercial use for highquality copies or electronic reprints for distribution to colleagues or customers please call     8 printed by patricia m millican  chief financial officer at metacrine inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink patricia m millican chief financial officer at metacrine inc overview in the news relationships paths education career history boards  committees transactions awards  honors patricia m millican chief financial officer at metacrine inc overview age  born  notable companies metacrine inc seragon pharmaceuticals inc awards  board seats  number of relationships this person is connected to 8 people in the news see more the san diego uniontribune august   metacrine has raised  million in vc fundsdrugmaking technology based on research from salk scientist pr newswire august   metacrine raises  million in series a financingappoints neil mcdonnell ceo along with executive team and board fiercebiotech april   salk heavyweight evans raising m for an intriguing stealth biotech relationships see details richard heyman scientific founder at metacrine inc irene oberbauer former president  chief executive officer at san diego county credit union nykia wilson employment counsel at petco animal supplies inc drew schlosberg host ut san diego prep sports report at wsradiocom linda amaro cofounder at klarinet solutions llc susan halliday chief financial officer at jewish federation of san diego county mathias schmidt president  chief executive officer at armagen inc chantal breyfogle former west region operations manager at sprint corp merrilee neal former professional at fallbrook martial arts inc karyn cerulli director of sales at entercom communications corp see 8 more listings with relsci professional start my free trial ➤ see 8 more paths to patricia m millican patricia m millican you connections via relationship science patricia m millican sync your contacts to see how you can connect with patricia m millican start my free trial ➤ see more educational background bs in accounting  university of san diego the university of san diego usd is a private roman catholic university in san diego california the university offers  baccalaureate degrees and several degrees in law nursing masters phd and dnpand other doctorate programs the university comprises seven different academic colleges career history chief financial officer   current metacrine inc metacrine inc engages in the development of therapeutics for metabolic diseases its focus is on the development of therapeutics for significant metabolic diseases such as type  diabetes and nonalcoholic steatohepatitis the company was founded by ronald m evans richard a heyman and michael downes in  and is headquartered in san diego ca chief financial officer prior   seragon pharmaceuticals inc seragon pharmaceuticals inc developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer the company was founded in  and is headquartered in san diego ca vice president of finance prior   aragon pharmaceuticals inc aragon pharmaceuticals inc develops biopharmaceutical products it offers a pipeline of new antiendocrine therapies targeting the biology of hormone resistant cancers the company was founded by charles l sawyers and michael jung on may   and is headquartered in san diego ca senior director  corporate controller    zogenix inc zogenix inc is a pharmaceutical company which engages in the development and commercialization of central nervous system cns therapies and products for the treatment orphan diseases and other cns disorders it develops two products candidate zx and relday the company was founded by stephen j farr cam l garner roger l hawley bret e megargel jonathan m n rigby scott l glenn and john j turanin on may   and is headquartered in emeryville ca chief accounting officer    metabasis therapeutics inc metabasis therapeutics inc engages in discovery development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liverselective drug targeting and treatment of metabolic diseases metabasis was incorporated in april  and is headquartered in la jolla ca professional prior discovery partners international inc discovery partners international inc dpi used to research laboratory looking to discovery pharmaceutical products it was a small molecule and natural product based drug discovery company that offered collaborations and services complementing the internal capabilities of pharmaceutical and biopharmaceutical discovery partners has actively contributed to dozens of drug discovery collaborations the company had operations in united states and europe the company was founded in  was headquartered in san diego ca professional prior ngen inc ngen inc advanced diagnostics provides physicians and patients worldwide with sophisticated information to predict diagnose and treat disease research and clinical reference labs use the highly accurate and reliable nanochipr molecular biology workstation nanochipr electronic microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems the synx subsidiary offers a line of pointofcare diagnostic tests and is building expertise in cardiac related health conditions nanogens ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics biowarfare and other industries the company is headquartered in san diego ca boards  committees nonprofit boards ▾ treasurer board of directors current susan g komen san diego since its inception in  komen san diego has raised more than  million to fund local nonprofits who provide everything from free diagnostic mammograms meal delivery temporary financial aid transportation and more seventyfive percent of every dollar raised in san diego stays in san diego county to fund breast health services for uninsured and underinsured women and their families the remaining  percent funds international breast cancer research in fact next to the us government susan g komen® is the largest funder of breast cancer research in the world transactions details hidden metacrine inc raised money in a private placement transaction awards  honors professional certification cpa certified public accountant sponsored by american institute of certified public accountants other affiliations patricia m millican is affiliated with metacrine inc seragon pharmaceuticals inc aragon pharmaceuticals inc zogenix inc metabasis therapeutics inc discovery partners international inc ngen inc susan g komen san diego youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ metacrine logo metacrine efficiently developing innovativedrugs that materially benefitpatients with metabolic disease about metacrine metacrine is a privately held biotech company founded in  on technology licensed from the laboratory of dr ronald evans a world leader in nuclear hormone receptors and howard hughes medical institute investigator at the salk institute metacrine will leverage two mechanistically distinct programs to target diabetes steatohepatitis and other metabolic and liver disorders learn more about metacrine latest news  metacrine to present two abstracts on its novel fxr nonbile acid agonist program at the easl international liver congress   metacrine expands patent portfolio for novel fgf program to treat diabetes see all news contact us metacrine inc 8 el camino real suite  san diego ca  p  8 f  8 information infometacrinecom employmentcareersmetacrinecom home about overview leadership board of directors scientific founders investors news contact x bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one